Top

Gepubliceerd in:

2017 | OriginalPaper | Hoofdstuk

20. Farmacotherapie persoonlijkheidsstoornissen

Auteurs : Dr. Theo Ingenhoven, Dr. Thomas Rinne

Gepubliceerd in: Handboek persoonlijkheidspathologie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Sinds de late jaren zeventig van de vorige eeuw is er voorzichtig optimisme ten aanzien van de effectiviteit van farmacotherapeutische interventies bij patiënten met een persoonlijkheidsstoornis, met name de borderlinepersoonlijkheidsstoornis (BPS). Er dient zich een groeiend aantal placebogecontroleerde gerandomiseerde studies aan waarin het effect van medicatie ten aanzien van specifieke symptomen van BPS in kaart wordt gebracht. Andere persoonlijkheidsstoornissen zijn veel minder onderzocht. Resultaten van placebogecontroleerd onderzoek maken duidelijk dat medicatie soms een behandeling kan ondersteunen, doordat op bepaalde symptoomgebieden van de persoonlijkheidsstoornissen winst te behalen valt, al is het maar in beperkte mate. In dit hoofdstuk bespreken we behandelalgoritmes van de meest toonaangevende behandelrichtlijnen voor persoonlijkheidsstoornissen (VS, Nederland, VK, Duitsland en Australië). We geven een kritisch overzicht van de gepubliceerde PC-RCT’s en meta-analyses die zich richten op specifieke symptoomdomeinen bij BPS (niet alleen primair op comorbide symptoomstoornissen). Op basis van deze uitkomsten wordt ten slotte een aantal aanbevelingen gepresenteerd.

vorige hoofdstuk Dialectische gedragstherapie

volgende hoofdstuk ‘Generalistische’ behandelingen voor persoonlijkheidsstoornissen: common features en factors

American Psychiatric Association. (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. American Journal of Psychiatry, 158, 1–52.

Binks, C., Fenton, M., McCarthy, L., et al. (2006). Pharmacological interventions for people with borderline personality disorder. Cochrane Database System Review, 3, CD005653.

Black, D. W., Zanarini, M. C., Romine, A., Shaw, M., Allen, J., & Schulz, S. C. (2014). Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: A randomized, double-blind, placebo-controlled trial. American Journal of Psychiatry, 171(11), 1174–1182.PubMed

Bogenschutz, M. P., & George, N. H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104–109.PubMed

Bouwman, R., Schulze, P. F. J., & Ingenhoven, T. (2013). Shared decision making: Samen kiezen, samen beslissen. Het farmacotherapeutisch spreekuur met borderlinepatiënten. Maandblad voor Geestelijke Volksgezondheid, 68, 208–215.

Broek, P. J. A. van den, Penterman, B. J. M., Hummelen, K. W., et al. (2008). The effect of quetiapine on psychotic-like symptoms and general psychopathology in patients with borderline personality disorder: A randomized placebo-controlled trial. European Neuropsychopharmacology, 18(4), S425–S426.

CBO (2008). Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Multidisciplinaire Richtlijn voor de diagnostiek en behandeling van volwassen patiënten met een persoonlijkheidsstoornis. Utrecht: Trimbos-instituut.

Coccaro, E. F., & Kavoussi, R. J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General psychiatry, 54, 1081–1088.PubMed

Cornelius, J. R., Soloff, P. H., George, A., Ulrich, R. F., & Perel, J. M. (1993a). Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacology Bulletin, 29, 333–337.PubMed

Cornelius, J. R., Soloff, P. H., Perel, J. M., & Ulrich, R. F. (1993b). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry, 150, 1843–1848.PubMed

Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111–119.PubMed

DGPPN. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (2009). Behandlungsleitlinie Persönlichkeitstörungen. Darmstadt: Steinkopff Verlag.

Farwell, W. R., Stump, T. E., Wang, J., Tafesse, E., L’Italien, G., & Tierney, W. M. (2004). Weight gain and new onset diabetes associated with olanzapine and risperidone. Journal of General Internal Medicine, 19, 1200–1205.PubMedPubMedCentral

Frankenburg, F. R. & Zanarini, M. C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442–446.

Fuente, J. M. de la, & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479–486.PubMed

Gardner, D. L., & Cowdry, R. W. (1985). Alprazolam-induced dyscontrol in borderline personality disorder. American Journal of Psychiatry, 142, 98–100.PubMed

Gardner, D. L., & Cowdry, R. W. (1986a). Possitive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry, 143, 519–522.PubMed

Gardner, D. L., & Cowdry, R. W. (1986b). Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology, 6, 236–239.PubMed

Goldberg, S. C., Schulz, S. C., Schulz, P. M., Resnick, R. J., Hamer, R. M., & Friedel, R. O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry, 43, 680–686.PubMed

Herpertz, S. C., Zanarini, M., Schulz, C. S., et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World Journal of Biological Psychiatry, 8, 212–244.PubMed

Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J., et al. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62, 199–203.PubMed

Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P., & Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621–624.PubMed

Hollander, E., Tracy, K. A., Swann, A. C., Coccaro, E. F., McElroy, S. L., Wozniak, P., et al. (2003). Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology, 28, 1186–1197.PubMed

Ingenhoven, T., Reekum, A. van, Luyn, B. van, & Luyten, P. (2012). Handboek borderline persoonlijkheidsstoornis. Utrecht: De Tijdstroom.

Ingenhoven, T., & Rinne, T. (2012). Farmacotherapeutische interventies. In T. Ingenhoven, A. van Reekum, B. van Luyn, & P. Luyten, Handboek borderline persoonlijkheidsstoornis. Utrecht, De Tijdstroom.

Ingenhoven, T., Lafay, P., Passchier, J., & Duivenvoorden, H. (2009). Een meta-analyse van de effecten van farmacotherapie bij persoonlijkheidsstoornissen. Actuele Kennis 12. Utrecht: Expertisecentrum Forensische Psychiatrie.

Ingenhoven, T., Lafay, P., Rinne, T., et al. (2010). Effectiveness of pharmacotherapy for severe personality disorders: Meta-analyses of randomized controlled trials. Journal of Clinical Psychiatry, 71, 14–25.PubMed

Ingenhoven, T., & Duivenvoorden, H. (2011). Differential effectiveness of antipsychotics in borderline personality disorder: Meta-analyses of placebo-controlled randomized clinical trials on specific symptomatic outcome domains. Journal of Clinical Psychopharmacology, 31(4), 489–496.PubMed

Koenigsberg, H. W., Reynolds, D., Goodman, M., New, A. S., Mitropoulou, V., Trestman, R. L., et al. (2003). Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry, 64, 628–634.PubMed

Lieb, K., Völlm, B., Rücker, G., et al. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry, 196, 4–12.PubMed

Lieberich, P., Nickel, M. K., Tritt, K., & Pedrosa Gil, F. (2008). Lamotrigine treatment of aggression in female borderline patients, part II: An 18-month follow-up. Journal of Psychopharmacology, 22(7), 805–808.

Linehan, M. M., McDavid, J. D., Brown, M. Z., et al. (2008). Olanzapine plus Dialectical Behavior Therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 69, 999–1005.PubMed

Links, P. S., Steiner, M., Boiago, I., & Irwin, D. (1990). Lithium therapy for borderline patients: Preliminary findings. Journal of personality Disorders, 4, 173–181.

Loew, T. H., Nickel, M. K., Meuhlbacher, M., Kaplan, P., Nickel, C., Kettler, C., et al. (2006). Topiramate treatment for women with borderline personality disorder. Journal of Clinical Psychopharmacology, 26, 61–66.PubMed

Loew, T. H., & Nickel, M. K. (2008). Topiramate treatment of women with borderline persoanlity disorder, part II: 18-month follow-up. Journal of Clinical Psychopharmacology, 28, 355–357.PubMed

Markovitz, P. (1995). Pharmacotherapy of impulsivity, aggression and related disorders. In E. Hollander & D. J. Stein (Red.), Impulsivity and aggression. New York: John Wiley & Sons.

Mercer, D., Douglass, A. B., & Links, P. S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of personality Disorders, 23(2), 156–174.PubMed

Moen, R., Freitag, M., Miller, M., Lee, S., Romine, A., Song, S., et al. (2012). Efficacy of extended-release divalproex combined with ‘condensed’ dialectical behavior therapy for individuals with borderline personality disorder. Annals of Clinical Psychiatry, 24, 255–260.PubMed

Montgomery, S. A., & Montgomery, D. (1982). Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291–298.PubMed

National Collaborating Centre for Mental Health. (2009). Borderline personality disorder: treatment and management. NICE clinical guideline 78. Londen: NICE.

National Health and Medical Research Council Australian Government (2013). Clinical practice guideline for the management of borderline personality disorder (geraadpleegd via: http://www.clinicalguidelines.gov.au).

Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., et al. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495–499.PubMed

Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K., et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515–1519.PubMed

Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Gil, F. P., Bachler, E., et al. (2006a). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833–838.PubMed

Nickel, M. K., & Loew, T. H. (2008). Treatment of aggression with topiramate in male borderline patients, part II: 18-month follow-up. European Psychiatry, 23(2), 115–117.PubMed

Nickel, M., Muehlbacher, M., Nickel, C., et al. (2006b). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833–838.PubMed

Nose, M., Cipriani, A., Biancosino, B., et al. (2006). Efficacy of pharmacotherapy against traits of borderline personality disorder: Meta-analysis of randomized controlled trails. International Clinical Psychopharmacology, 21, 345–353.PubMed

Oldham, J. M. (2005). Guideline watch: practice guideline for the treatment of patients with borderline personality disorder. Arlington, VA: American Psychiatric Association. Available online at http://www.psych.org/psych_pract/treatg/pg/prac_guide.cmf.

Pascual, J. C., Soler, J., Puigdemont, D., et al. (2008). Ziprazidone in the treatment of borderline personality disorder: A double-blind, placebo-controlled, randomized study. Journal of Clinical Psychiatry, 69(4), 603–608.PubMed

Philipsen, A., Schmahl, C., & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196–199.PubMed

Reich, D. B., Zanarini, M. C., & Bieri, K. A. (2009). A priliminairy study of lamotrigine in the treatment of affective instability in borderline personality disorder. International Clinical Psychopharmacology, 24, 270–275.PubMed

Rinne, T., & Ingenhoven, T. (2007). Pharmacotherapy of severe personality disorders: a critical review. In: Luyn, B. van, Akhtar, S. & Livesley, J. (Eds.). Severe personality disorders. Everyday issues in clinical practice. Cambridge: Cambridge University Press.

Rinne, T., Brink, W. van den, Wouters, L., & Dyck, R. van. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159(12), 2048–2054.PubMed

Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal Clinical Psychopharmacology, 15, 23–29.

Schmahl, C., Kleindienst, N., Limberger, P., Mauchnik, J., Deibier, P., Brünen, S., et al. (2012). Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International Clinical Psychopharmacology, 27, 61–68.PubMed

Schulz, S. C., Zanarini, M., Detke, H., et al. (2006). Olanzapine for the treatment of borderline personality disorder: A flexible-dose12-week randomized double-blind placebo-controlled study. P101. Presented at the XXIVth CINP Congress, Chicago, USA, 9–13 July. International Journal of Neuropsychopharmacology, 9(1), S191.

Schulz, S. C., Zanarini, M. C., Bateman, A., et al. (2008). Olanzapine for the treatment of borderline personality disorder: Variable dose 12-week randomized double-blind placebo-controlled study. British Journal of Psychiatry, 193, 485–492.PubMed

Schulz, S. C., & Nelson, K. J. (2014). Somatic treatments. In Oldham, J. M., Skodo, A. E., & Bender, D. S. (Eds.), Textbook of personality disorders, DSM (5 ed.). Arlington: The American Psychiatric Publishing.

Shafti, S. S., & Shahveisi, B. (2010). Olanzapine versus haloperidol in the management of borderline personality disorder. A randomized double-blind trial. Journal of Clinical Psychopharmacology, 30(1), 44–47.PubMed

Siever, L. J., & Davis, K. L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647–1658.

Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J., et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379–385.PubMed

Soler, J., Pascual, J. C., Campins, M. J., Barrachina, J., Puigdemont, D., Alvarez, E., et al. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221–1224.PubMed

Soloff, P. H. (1998). Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic, 62, 195–214.PubMed

Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America, 23, 169–192.PubMed

Soloff, P. H., Cornelius, J., George, A., Nathan, S., Perel, J. M., & Ulrich, R. F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377–385.PubMed

Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., & Perel, J. M. (1986a). Paradoxical effects of amitriptyline on borderline patients. American Journal of Psychiatry, 143, 1603–1605.PubMed

Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M., Ulrich, R. F., & Perel, J. M. (1986b). Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Archives of General Psychiatry, 43, 691–697.PubMed

Soloff, P. H., George, A., Nathan, S., Schulz, P. M., Cornelius, J. R., Herring, J., et al. (1989). Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology, 9, 238–246.PubMed

Tritt, K., Nickel, C., Lahmann, C., Lieberich, P. K., Rother, W. K., Loew, T. H., et al. (2005). Lamotrigine treatment of aggression in female borderline patients: A randomized, double-blind, placebo-controlled study. Journal of Psychofarmacology, 19(3), 287–291.

Verkes, R. J., Fekkes, D., Zwinderman, A. H., Hengeveld, M. W., Mast, R. C. van der, Tuyl, J. P., et al. (1997). Platelet serotonine and [³H]paroxetine binding correlate with recurrence of suicidal behavior. Psychopharmacology, 132, 89–94.PubMed

Verwey, B., & Ingenhoven, T. (2015). Farmacotherpeutische en andere biologische behandelingen van suïcidaliteit. In A. Kerkhof, & B. van Luyn (Red.), Behandeling van suïcidaal gedrag in de praktijk van de GGZ. Houten: Bohn Stafleu van Loghum.

Vita, A., Peri, L. de, & Sacchetti, E. (2011). Antipsychotics, antidepressants, anticonvulsants, and placebo on symptom dimensions of borderline personality disorder. A meta-analysis of randomized controlled and open trials. Journal of Clinical Psychopharmacology, 31, 613–624.PubMed

Willems, A. E., Tenback, D. E., Ingenhoven, T. J. M., & Harten, P. N. van. (2014). Acute movement disorders associated with the use of second generation antipsychotics in borderline personality disorder: A meta-analysis. Journal of Clinical Psychopharmacology, 34(4), 520–522.PubMed

Zanarini, M. C., & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849–854.PubMed

Zanarini, M. C., & Frankenburg, F. R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167–169.PubMed

Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903–907.PubMed

Zanarini, M. C., Schulz, C., Detke, H. C., Tanaka, Y., Zhao, F., Lin, D., et al. (2006). A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12-week randomized, double-blind, placebo-controlled study. 25^th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum, Chicago, Il.

Ziegenhorn, A. A., Roepke, S., Schommer, N. C., Merkl, A., Danker-Hopfe, H., Perschel, F. H., et al. (2009). Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder. Journal of Clinical Psychopharmacology, 29, 170–173.PubMed

Titel: Farmacotherapie persoonlijkheidsstoornissen
Auteurs: Dr. Theo Ingenhoven
Dr. Thomas Rinne
Uitgeverij: Bohn Stafleu van Loghum
Boek: Handboek persoonlijkheidspathologie
Print ISBN: 978-90-368-0930-6

Elektronisch ISBN: 978-90-368-0931-3

Copyright: 2017
DOI: https://doi.org/10.1007/978-90-368-0931-3_20

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen